49 results
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
6 Dec 23
Current report (foreign)
5:19pm
, at least a majority of the persons serving on the Board of Directors qualify as "independent," as defined under the listing rules of the Exchange.
2.31 … of shares of Common Stock pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
20 Oct 23
Current report (foreign)
2:56pm
of that broker. In Canada, the vast majority of such Common Shares are registered under the name of CDS & Co., being the registration name … and returned in accordance with the specific instructions noted on the VIF.
The majority of intermediaries now delegate responsibility for obtaining
6-K
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
9 Aug 23
Immunoprecise Antibodies LTD. 6-K
9:15am
”) in its search for the optimal Board composition.
Majority Voting Policy
Furthermore, in its commitment to address shareholders’ concerns … and as part of its continuous review and improvement process, the Company announced that the Board has also adopted a majority voting policy (the “Majority
F-3
EX-4.3
IPA
ImmunoPrecise Antibodies Ltd
10 Jul 23
Shelf registration (foreign)
7:04pm
by either Trustee as hereinafter provided in this Article Five, the Holders of a majority in principal amount of the Outstanding Securities … to the Trustees during such 60-day period by the Holders of a majority or more in principal amount of the Outstanding Securities of that series in the case of any
40-F
2023 FY
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
10 Jul 23
Annual report (Canada)
4:32pm
of British Columbia, with its registered place of business in Canada, some of its directors and officers reside outside the United States and the majority … ”) comprised of not less than three directors, a majority of whom are not officers, control persons or employees of the Company or an affiliate
6-K
EX-99.1
qkvlcl7
24 Apr 23
Current report (foreign)
10:01am
6-K
EX-99.1
no2k4qfz
15 Dec 22
Current report (foreign)
8:00am
6-K
EX-99.2
y98brw
17 Nov 22
Current report (foreign)
9:36am
6-K
EX-99.1
upjr7ffgtk7suo9hrq
14 Sep 22
Current report (foreign)
8:31am
40-F
EX-99.1
dqagi
29 Jul 22
Annual report (Canada)
9:04am
40-F
EX-99.3
gfojyn1s l0wq94rxa
29 Jul 22
Annual report (Canada)
9:04am
6-K
EX-99.2
mqfh6dz3kzzi
14 Apr 22
Current report (foreign)
10:18am
6-K
EX-99.1
bjttr7x7
16 Mar 22
FY22 Q3 6-K
8:00am
6-K
EX-99.2
f5r0s1041zu0ei5d2iz
13 Dec 21
Ipa FY22 Q2 6-K
8:57am
6-K
EX-99.1
a3qcwpp20l9sn 13en
12 Nov 21
Current report (foreign)
8:58am
SUPPL
cu3qaub7iua z36y
13 Oct 21
Supplemental materials (foreign)
5:29pm
6-K
EX-99.1
rk8b9aidi5bt
9 Sep 21
Immunoprecise Antibodies LTD. 6-K
8:28am
6-K
EX-99.2
9bgoafy yq2u2pt7
9 Sep 21
Ipa FY22 Q1 6-K Filing
8:28am
40-F
EX-99.2
p4dzptp7p a2em2d
28 Jul 21
Annual report (Canada)
8:01am
40-F
EX-99.1
7ezhiu3u6wrti
28 Jul 21
Annual report (Canada)
8:01am